{"drugs":["Azasan","Azathioprine","Imuran"],"mono":[{"id":"51765-s-0","title":"Generic Names","mono":"Azathioprine"},{"id":"51765-s-1","title":"Dosing and Indications","sub":[{"id":"51765-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Renal transplant rejection, Adjunct; Prophylaxis:<\/b> (initial) 3 to 5 mg\/kg as a single daily dose starting at the time of transplant; less commonly, therapy is started 1 to 3 days prior to transplantation; IV azathioprine therapy (as sodium salt) is typically administered initially, and then patients are switched to oral therapy (at the same dosage) after the postoperative period<\/li><li><b>Renal transplant rejection, Adjunct; Prophylaxis:<\/b> (maintenance) 1 to 3 mg\/kg\/day ORALLY<\/li><li><b>Rheumatoid arthritis:<\/b> (initial) 1 mg\/kg\/day ORALLY as single dose or divided twice daily; may titrate by 0.5 mg\/kg\/day after 6 to 8 wk and every 4 weeks thereafter; MAX dose is 2.5 mg\/kg\/day<\/li><li><b>Rheumatoid arthritis:<\/b> (maintenance) may lower dose 0.5 mg\/kg\/day every 4 wk (while keeping other drug therapy constant) until lowest effective dose is reached<\/li><\/ul>"},{"id":"51765-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy not established in pediatric patients "},{"id":"51765-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>hematologic toxicity:<\/b> decrease the dosage or withhold therapy in patients who experience a rapid fall in or persistently low leucocyte counts or other signs of bone marrow depression; consider discontinuing therapy if CBC abnormalities persist despite dosage reduction<\/li><li><b>reduced thiopurine S-methyltransferase (TPMT) activity:<\/b> dosage reduction recommended<\/li><li><b>renal impairment:<\/b> usually administered at lower doses<\/li><\/ul>"},{"id":"51765-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Renal transplant rejection, Adjunct; Prophylaxis<\/li><li>Rheumatoid arthritis<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Atopic dermatitis<\/li><li>Inflammatory bowel disease<\/li><li>Liver transplant rejection; Prophylaxis<\/li><li>Myasthenia gravis<\/li><li>Rejection of pancreas transplant; Prophylaxis<\/li><li>Sprue, Refractory<\/li><li>Systemic lupus erythematosus<\/li><li>Takayasu's disease<\/li><li>Vasculitis<\/li><\/ul>"}]},{"id":"51765-s-2","title":"Black Box Warning","mono":"<b>Oral (Tablet)<\/b><br\/>Chronic immunosuppression with azathioprine increases risk of malignancy in humans. Reports of malignancy include post-transplant lymphoma and hepatosplenic T-cell lymphoma (HSTCL) in patients with inflammatory bowel disease. Physicians using this drug should be very familiar with this risk as well as with the mutagenic potential to both men and women and with possible hematologic toxicities. Inform patients of the malignancy risks.<br\/>"},{"id":"51765-s-3","title":"Contraindications\/Warnings","sub":[{"id":"51765-s-3-9","title":"Contraindications","mono":"<ul><li>hypersensitivity to azathioprine<\/li><li>pregnant women with rheumatoid arthritis<\/li><li>rheumatoid arthritis, prior treatment with alkylating agents (eg, cyclophosphamide, chlorambucil, melphalan, or others); increased risk of malignancy<\/li><\/ul>"},{"id":"51765-s-3-10","title":"Precautions","mono":"<ul><li>hematologic toxicities may occur; including leukopenia, thrombocytopenia, macrocytic anemia, and pancytopenia; monitoring recommended; dose adjustment or treatment interruption may be required<\/li><li>malignancy may occur, including skin cancer, myelogenous leukemia in rheumatoid arthritis patients, post-transplant reticulum cell or lymphomas, and hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease, especially in adolescent and young adult males; monitoring recommended; dose adjustment or treatment interruption may be required<\/li><li>concomitant use with disease-modifying antirheumatic drugs is not recommended<\/li><li>gastrointestinal hypersensitivity reaction, characterized by severe nausea and vomiting and possibly diarrhea, rash, fever, malaise, myalgias, liver enzyme elevations, and hypotension, has been reported, usually during initial therapy and may recur on rechallenge<\/li><li>infections, serious, including opportunistic, new, or reactivated latent infections, may occur<\/li><li>progressive multifocal leukoencephalopathy (PML) associated with JC virus infection, including fatalities, has been reported; consider dose reduction if condition occurs<\/li><li>renal transplant patients experiencing rejection; increased risk of hematologic toxicity; monitoring recommended; dose adjustment or discontinuation may be required<\/li><li>thiopurine S-methyl transferase (TPMT) deficiency; increased risk of severe myelotoxicity; baseline TPMT genotype or phenotype testing recommended; consider alternate therapy, dose reduction, or discontinuation for patients with reduced TMPT activity<\/li><li>women of childbearing potential; known teratogen; avoid pregnancy<\/li><\/ul>"},{"id":"51765-s-3-11","title":"Pregnancy Category","mono":"<ul><li>D (FDA)<\/li><li>D (AUS)<\/li><\/ul>"},{"id":"51765-s-3-12","title":"Breast Feeding","mono":"<ul><li>WHO: Avoid breastfeeding.<\/li><li>Micromedex: Infant risk cannot be ruled out.<\/li><\/ul>"}]},{"id":"51765-s-4","title":"Drug Interactions","sub":[{"id":"51765-s-4-13","title":"Contraindicated","mono":"<ul>Febuxostat (theoretical)<\/ul>"},{"id":"51765-s-4-14","title":"Major","mono":"<ul><li>Adenovirus Vaccine Type 4, Live (established)<\/li><li>Adenovirus Vaccine Type 7, Live (established)<\/li><li>Alacepril (theoretical)<\/li><li>Alfalfa (probable)<\/li><li>Allopurinol (established)<\/li><li>Bacillus of Calmette and Guerin Vaccine, Live (established)<\/li><li>Benazepril (theoretical)<\/li><li>Black Cohosh (probable)<\/li><li>Captopril (established)<\/li><li>Cilazapril (theoretical)<\/li><li>Doxorubicin (established)<\/li><li>Doxorubicin Hydrochloride Liposome (established)<\/li><li>Enalaprilat (probable)<\/li><li>Enalapril Maleate (probable)<\/li><li>Fosinopril (theoretical)<\/li><li>Influenza Virus Vaccine, Live (established)<\/li><li>Lisinopril (theoretical)<\/li><li>Measles Virus Vaccine, Live (established)<\/li><li>Mercaptopurine (theoretical)<\/li><li>Moexipril (theoretical)<\/li><li>Mumps Virus Vaccine, Live (established)<\/li><li>Mycophenolic Acid (theoretical)<\/li><li>Olsalazine (probable)<\/li><li>Oxypurinol (established)<\/li><li>Pentopril (theoretical)<\/li><li>Perindopril (theoretical)<\/li><li>Poliovirus Vaccine, Live (established)<\/li><li>Quinapril (theoretical)<\/li><li>Ramipril (theoretical)<\/li><li>Ribavirin (probable)<\/li><li>Rotavirus Vaccine, Live (established)<\/li><li>Rubella Virus Vaccine, Live (established)<\/li><li>Smallpox Vaccine (established)<\/li><li>Spirapril (theoretical)<\/li><li>Sulfamethoxazole (theoretical)<\/li><li>Sulfasalazine (theoretical)<\/li><li>Trandolapril (theoretical)<\/li><li>Trimethoprim (theoretical)<\/li><li>Typhoid Vaccine (established)<\/li><li>Varicella Virus Vaccine (established)<\/li><li>Yellow Fever Vaccine (established)<\/li><li>Zofenopril (theoretical)<\/li><\/ul>"},{"id":"51765-s-4-15","title":"Moderate","mono":"<ul><li>Acenocoumarol (probable)<\/li><li>Cyclosporine (probable)<\/li><li>Phenprocoumon (probable)<\/li><li>Warfarin (probable)<\/li><\/ul>"}]},{"id":"51765-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Gastrointestinal:<\/b>Nausea and vomiting (12%)<br\/><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Pericarditis<\/li><li><b>Gastrointestinal:<\/b>Pancreatitis, Hypersensitivity<\/li><li><b>Hematologic:<\/b>Acute myeloid leukemia, Hematologic toxicity, Leukopenia (renal transplant, more than 50%; rheumatoid arthritis, 28%), Leukopenia (Severe), Less than 2500 cells\/mm[3] (renal transplant, 16%; rheumatoid arthritis, 5.3%), Macrocytic anemia, Myelodysplastic syndrome, Myelosuppression (5%), Pancytopenia, Thrombocytopenia<\/li><li><b>Hepatic:<\/b>Hepatotoxicity (less than 1%), Lymphoma involves liver, Veno-occlusive disease of the liver<\/li><li><b>Immunologic:<\/b>Hypersensitivity reaction, Malignant lymphoma (0.5%), T-cell lymphoma, Hepatosplenic<\/li><li><b>Neurologic:<\/b>Progressive multifocal leukoencephalopathy<\/li><li><b>Respiratory:<\/b>Adenocarcinoma of lung<\/li><li><b>Other:<\/b>Infectious disease (renal transplant, 20%; rheumatoid arthritis, less than 1%), Neoplastic disease (0.5% to 2.8%)<\/li><\/ul>"},{"id":"51765-s-6","title":"Drug Name Info","sub":{"0":{"id":"51765-s-6-17","title":"US Trade Names","mono":"<ul><li>Azasan<\/li><li>Imuran<\/li><\/ul>"},"2":{"id":"51765-s-6-19","title":"Class","mono":"<ul><li>Antimetabolite<\/li><li>Antirheumatic, Cytotoxic<\/li><\/ul>"},"3":{"id":"51765-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"51765-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},{"id":"51765-s-7","title":"Mechanism Of Action","mono":"Azathioprine is an imidazolyl derivative of 6-mercaptopurine and acts as an immunosuppressive antimetabolite. The exact mechanism of immunosuppressive action is unknown because the exact mechanism of the immune response itself is complex and not completely understood. Azathioprine suppresses cell-mediated hypersensitivities and causes alterations in antibody production.<br\/>"},{"id":"51765-s-8","title":"Pharmacokinetics","sub":[{"id":"51765-s-8-23","title":"Absorption","mono":"<ul><li>Azathioprine (prodrug), oral: well absorbed<\/li><li>6-mercaptopurine (active drug), Bioavailability, Oral: 47.4%<\/li><li>6-mercaptopurine (active drug), Bioavailability, Rectal: 1.3% to 5.3%<\/li><li>6-mercaptopurine (active drug), Tmax, Oral: 1 to 2 hr<\/li><li>6-mercaptopurine (active drug), Tmax, Rectal: 2 hr<\/li><\/ul>"},{"id":"51765-s-8-24","title":"Distribution","mono":"<ul><li>Vd: 0.808 L\/kg (prodrug, IV dose)<\/li><li>Protein binding: 30% (azathioprine and mercaptopurine)<\/li><\/ul>"},{"id":"51765-s-8-25","title":"Metabolism","mono":"<ul><li>Azathioprine (prodrug), Liver: extensive oxidation or methylation<\/li><li>Azathioprine (prodrug), Erythrocytes: oxidation or methylation<\/li><li>6-Mercaptopurine: active<\/li><li>6-Thioguanine nucleotides (6-TGNs): active<\/li><\/ul>"},{"id":"51765-s-8-26","title":"Excretion","mono":"<ul><li>Renal clearance: 57.3 mL\/min\/kg (prodrug IV administration)<\/li><li>Dialyzable: Yes, 45% over 8 hr<\/li><\/ul>"},{"id":"51765-s-8-27","title":"Elimination Half Life","mono":"5 hr (35-S-azathioprine-containing metabolites).<br\/>"}]},{"id":"51765-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>use proper procedures for handling and disposal of immunosuppressant agents<br\/><\/li><li><b>Oral<\/b><br\/>take as a single daily dose or in divided doses or with food to decrease gastrointestinal intolerance<br\/><\/li><\/ul>"},{"id":"51765-s-10","title":"Monitoring","mono":"<ul><li>renal homotransplantation: prevention of rejection<\/li><li>rheumatoid arthritis: improved range of motion, decreased early morning stiffness and painful\/swollen joints, C-reactive protein levels, erythrocyte sedimentation rate<\/li><li>CBC, platelets counts; weekly during first month; twice monthly during second and third months; then monthly (more often when therapy\/dosage changes)<\/li><li>liver function; every 2 weeks during first month, monthly thereafter<\/li><\/ul>"},{"id":"51765-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/>Oral Tablet: 50 MG<br\/><\/li><li><b>Azasan<\/b><br\/>Oral Tablet: 75 MG, 100 MG<br\/><\/li><li><b>Imuran<\/b><br\/>Oral Tablet: 50 MG<br\/><\/li><\/ul>"},{"id":"51765-s-12","title":"Toxicology","sub":[{"id":"51765-s-12-31","title":"Clinical Effects","mono":"<b>AZATHIOPRINE\/MERCAPTOPURINE <\/b><br\/>OVERDOSE: Nausea, vomiting, diarrhea, delayed leukopenia, increased SGOT and bilirubin, and impaired renal function can occur in overdose. ADVERSE EFFECTS: Fever, hepatitis, pancreatitis, skin rashes, and alopecia have developed Myelosuppression is the dose-limiting toxicity.<br\/>"},{"id":"51765-s-12-32","title":"Treatment","mono":"<b>AZATHIOPRINE\/MERCAPTOPURINE <\/b><br\/><ul><li>Decontamination: Activated charcoal<\/li><li>Support: Care is symptomatic and supportive.<\/li><li>Neutropenia: Severe neutropenia: filgrastim 5 mcg\/kg\/day subcutaneously, or sargramostim 250 mcg\/m(2)\/day infused over 4 hrs.<\/li><li>Enhanced elimination procedure: Azathioprine and metabolites are hemodialyzable<\/li><li>Monitoring of patient: Serial CBC with differential due to possible delayed neutropenia, hepatic enzymes and renal function<\/li><\/ul>"},{"id":"51765-s-12-33","title":"Range of Toxicity","mono":"<b>AZATHIOPRINE\/MERCAPTOPURINE<\/b><br\/>TOXIC DOSE: Not established. Transient neutropenia reported after azathioprine 7500 mg in an adult and 1 g (86 mg\/kg) in a toddler. No toxicity developed in an adult after 850 mg azathioprine. A toddler remained asymptomatic after up to 400 mg (26 mg\/kg) of 6-mercaptopurine. THERAPEUTIC: Azathioprine: 1 to 5 mg\/kg\/day orally. 6-mercaptopurine: 2.5 to 5 mg\/kg\/day orally.<br\/>"}]},{"id":"51765-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient of increased risk of malignancies and to report persistent fevers, night sweats, or significant weight loss.<\/li><li>This drug may cause myelosuppression and gastrointestinal toxicity.<\/li><li>Instruct patient to report any unusual bleeding or bruising.<\/li><li>Instruct patient to report signs\/symptoms of infection.<\/li><li>Patient may take drug with food or in divided doses to decrease gastrointestinal intolerance.<\/li><li>Advise patient there are multiple significant drug-drug interactions for this drug. Consult healthcare professional prior to new drug use (including over-the-counter and herbal drugs).<\/li><\/ul>"}]}